EARLY DETECTION OF NEPHROTOXIC EFFECTS IN THALASSEMIC PATIENTS RECEIVING DESFERRIOXAMINE THERAPY
EARLY DETECTION OF NEPHROTOXIC EFFECTS IN THALASSEMIC PATIENTS RECEIVING DESFERRIOXAMINE THERAPY
复制标题
DOI：
10.1038/ki.1994.295
复制
发表时间：
1994-08-01
影响因子：
19.6
通讯作者：
CARTA, S
中科院分区：
文献类型：
--
作者：
CIANCIULLI, P;SOLLECITO, D;CARTA, S
早期检测接受去铁胺治疗的地中海贫血患者的肾毒性作用。该研究包括 19 名输血依赖性β-地中海贫血重度患者。其中 6 名患者通过皮下输注（50 mg/kg/12 小时）接受去铁胺螯合治疗，13 名患者接受静脉输注（50 mg/kg/6 小时或 100 mg/kg/24 小时）。在去铁胺治疗期间评估BUN、肌酐、肌酐清除率、β(2)-微球蛋白、尿β(2)-微球蛋白和尿生长激素排泄量。 19 名患者中有 13 名出现肾小管损伤，表现为尿 β(2)-微球蛋白排泄增加。 85%（13 名患者中的 11 名）表现出更严重的肾小管损伤，尿生长激素排泄同时增加就证明了这一点。此外，尿生长激素排泄量与尿β(2)-微球蛋白呈正相关(P < 0.05)。
Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Nineteen transfusion-dependent beta-thalassemia major patients were included in the study. Six of these patients underwent chelation therapy with desferrioxamine by subcutaneous infusion (50 mg/kg/12 hr) and 13 received intravenous infusion (50 mg/kg/6 hr or 100 mg/kg/24 hr). BUN, creatinine, creatinine clearance, beta(2)-microglobulin, urinary beta(2)-microglobulin and urinary growth hormone excretion were evaluated during desferrioxamine treatment. Thirteen out of nineteen patients presented tubular damage indicated by increased excretion of urinary beta(2)-microglobulin. 85% (11 of 13) of these patients showed more serious tubular damage, as demonstrated by concurrent increased urinary growth hormone excretion. Moreover, a positive correlation between urinary growth hormone excretion and urinary beta(2)-microglobulin was observed (P < 0.05).